{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T12:00:40Z","timestamp":1788091240533,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AR073927"],"award-info":[{"award-number":["K23AR073927"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options in Rheum"],"DOI":"10.1007\/s40674-022-00193-6","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T10:03:22Z","timestamp":1658829802000},"page":"71-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Past, Present, and Future in Dermatomyositis Therapeutics"],"prefix":"10.1007","volume":"8","author":[{"given":"Melody P.","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8436-1601","authenticated-orcid":false,"given":"Julie J.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"issue":"5","key":"193_CR1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","volume":"14","author":"CV Oddis","year":"2018","unstructured":"Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14(5):279\u201389. https:\/\/doi.org\/10.1038\/nrrheum.2018.42.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"193_CR2","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/art.41762","volume":"73","author":"IE Lundberg","year":"2021","unstructured":"\u2022 Lundberg IE. Expert perspective: management of refractory inflammatory myopathy. Arthritis Rheumatol. 2021;73(8):1394\u2013407. https:\/\/doi.org\/10.1002\/art.41762. A comprehensive evidence-based review summarizing treatment strategies for refractory inflammatory myopathy.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"193_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-020-00943-2","volume":"22","author":"LN Smith","year":"2020","unstructured":"Smith LN, Paik JJ. Promising and upcoming treatments in myositis. Curr Rheumatol Rep. 2020;22(10):65. https:\/\/doi.org\/10.1007\/s11926-020-00943-2.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"193_CR4","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/annrheumdis-2017-212047","volume":"77","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77(5):720\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212047.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"193_CR5","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","volume":"73","author":"JJ Paik","year":"2021","unstructured":"\u2022\u2022 Paik JJ, Casciola-Rosen L, Shin JY, et al. Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. Arthritis Rheumatol. 2021;73(5):858\u201365. https:\/\/doi.org\/10.1002\/art.41602. This is the first prospective, open-label clinical trial of tofacitinib in dermatomyositis that demonstrated strong clinical efficacy in dermatomyositis patients based on validated myositis response criteria.","journal-title":"Arthritis Rheumatol"},{"key":"193_CR6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tj\u00e4rnlund","year":"2018","unstructured":"Tj\u00e4rnlund A, Tang Q, Wick C, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77:55\u201362.","journal-title":"Ann Rheum Dis"},{"key":"193_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/annrheumdis-2021-eular.1389","volume":"80","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, et al. OP0008 a randomized, double-blind, placebo-controlled phase iii trial of IVIg 10% in patients with dermatomyositis. The ProDERM study: results on efficacy and safety. Ann Rheum Dis. 2021;80:4\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"193_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0190-9622(97)70327-x","volume":"36","author":"JS Kasteler","year":"1997","unstructured":"Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67\u201371. https:\/\/doi.org\/10.1016\/s0190-9622(97)70327-x.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"193_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","volume":"1","author":"ED Newman","year":"1995","unstructured":"Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1(2):99\u2013102. https:\/\/doi.org\/10.1097\/00124743-199504000-00007.","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"193_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-i","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe MM, Love LA, Leff RL, et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94(4):379\u201387. https:\/\/doi.org\/10.1016\/0002-9343(93)90148-i.","journal-title":"Am J Med"},{"issue":"5","key":"193_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/0190-9622(95)91455-2","volume":"32","author":"ME Zieglschmid-Adams","year":"1995","unstructured":"Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5):754\u20137. https:\/\/doi.org\/10.1016\/0190-9622(95)91455-2.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"193_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","volume":"56","author":"A Bohan","year":"1977","unstructured":"Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore). 1977;56(4):255\u201386. https:\/\/doi.org\/10.1097\/00005792-197707000-00001.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"193_CR13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","volume":"41","author":"L Villalba","year":"1998","unstructured":"Villalba L, Hicks JE, Adams EM, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41(3):392\u20139. https:\/\/doi.org\/10.1002\/1529-0131(199803)41:3%3c392::AID-ART3%3e3.0.CO;2-X.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"193_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","volume":"46","author":"CN Pisoni","year":"2007","unstructured":"Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D\u2019Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford). 2007;46(3):516\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/kel336.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"193_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006;66(8):1245\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000208416.32471.c0.","journal-title":"Neurology"},{"issue":"9","key":"193_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","volume":"15","author":"I Elovaara","year":"2008","unstructured":"Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893\u2013908. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02246.x.","journal-title":"Eur J Neurol"},{"issue":"5","key":"193_CR17","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/mus.21433","volume":"40","author":"PD Donofrio","year":"2009","unstructured":"Donofrio PD, Berger A, Brannagan TH, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009;40(5):890\u2013900. https:\/\/doi.org\/10.1002\/mus.21433.","journal-title":"Muscle Nerve"},{"issue":"27","key":"193_CR18","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993\u20132000. https:\/\/doi.org\/10.1056\/NEJM199312303292704.","journal-title":"N Engl J Med"},{"issue":"2","key":"193_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin P, Pelletier S, Teixeira A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46(2):467\u201374. https:\/\/doi.org\/10.1002\/art.10053.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"193_CR20","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76(5):792\u2013801. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211400.","journal-title":"Ann Rheum Dis"},{"key":"193_CR21","unstructured":"\u2022\u2022 Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie M, Griger Z, Moiseev S, Oddis C, Schiopu E, Vencovsky J, Beckmann I, Clodi E, Levine T, Investigators a. Safety and tolerability of IVIg (Octagam 10%) in patients with active dermatomyositis. Results of a randomized, double-blind, placebo-controlled phase III trial [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 10). https:\/\/acrabstracts.org\/abstract\/safety-and-tolerability-of-ivig-octagam-10-in-patients-with-active-dermatomyositis-results-of-a-randomized-double-blind-placebo-controlled-phase-iii-trial\/. Accessed 27 Jan 2022. Preliminary results from the ProDERM study demonstrated that IVIg is safe and efficacious in dermatomyositis subjects."},{"issue":"3","key":"193_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev. 2011;10(3):144\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2010.09.004.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"193_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314\u201324. https:\/\/doi.org\/10.1002\/art.37754.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"193_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2017;56(2):247\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/kew396.","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"193_CR25","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","volume":"371","author":"T Hornung","year":"2014","unstructured":"Hornung T, Janzen V, Heidgen FJ, Wolf D, Bieber T, Wenzel J. Remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2014;371(26):2537\u20138. https:\/\/doi.org\/10.1056\/NEJMc1412997.","journal-title":"N Engl J Med"},{"issue":"13","key":"193_CR26","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMc1500688","volume":"372","author":"A Selva-O\u2019Callaghan","year":"2015","unstructured":"Selva-O\u2019Callaghan A, Trallero-Aragu\u00e1s E, Labrador-Horrillo M. More on remission of recalcitrant dermatomyositis treated with ruxolitinib. N Engl J Med. 2015;372(13):1273\u20134. https:\/\/doi.org\/10.1056\/NEJMc1500688.","journal-title":"N Engl J Med."},{"issue":"3","key":"193_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1136\/ard.2011.150284","volume":"71","author":"S Rosengren","year":"2012","unstructured":"Rosengren S, Corr M, Firestein GS, Boyle DL. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis. 2012;71(3):440\u20137. https:\/\/doi.org\/10.1136\/ard.2011.150284.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"193_CR28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/rheumatology\/key366","volume":"58","author":"S Moghadam-Kia","year":"2019","unstructured":"Moghadam-Kia S, Charlton D, Aggarwal R, Oddis CV. Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. Rheumatology (Oxford). 2019;58(6):1011\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/key366.","journal-title":"Rheumatology (Oxford)"},{"issue":"37","key":"193_CR29","doi-asserted-by":"publisher","first-page":"e21943","DOI":"10.1097\/MD.0000000000021943","volume":"99","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa Y, Kasuya T, Fujiwara M, Kita Y. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: a case report. Medicine (Baltimore). 2020;99(37):e21943. https:\/\/doi.org\/10.1097\/MD.0000000000021943.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"193_CR30","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","volume":"46","author":"JJ Paik","year":"2017","unstructured":"Paik JJ, Christopher-Stine L. A case of refractory dermatomyositis responsive to tofacitinib. Semin Arthritis Rheum. 2017;46(4):e19. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.08.009.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"193_CR31","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","volume":"141","author":"L Ladislau","year":"2018","unstructured":"Ladislau L, Su\u00e1rez-Calvet X, Toquet S, et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain. 2018;141(6):1609\u201321. https:\/\/doi.org\/10.1093\/brain\/awy105.","journal-title":"Brain"},{"issue":"3","key":"193_CR32","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/ddg.14276","volume":"19","author":"I Navarro-Navarro","year":"2021","unstructured":"Navarro-Navarro I, Jim\u00e9nez-Gallo D, Rodr\u00edguez-Mateos ME, Rodr\u00edguez-Hern\u00e1ndez C, Linares-Barrios M. Treatment of refractory anti-NXP2 and anti-TIF1\u03b3 dermatomyositis with tofacitinib. J Dtsch Dermatol Ges. 2021;19(3):443\u20137. https:\/\/doi.org\/10.1111\/ddg.14276.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"193_CR33","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 2016;152(8):944\u20135. https:\/\/doi.org\/10.1001\/jamadermatol.2016.0866.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"193_CR34","doi-asserted-by":"publisher","first-page":"adv00144","DOI":"10.2340\/00015555-3481","volume":"100","author":"T Fetter","year":"2020","unstructured":"Fetter T, Rios GC, Niebel D, Bieber T, Wenzel J. Unexpected hair regrowth in a patient with longstanding Alopecia Universalis during treatment of recalcitrant dermatomyositis with the Janus kinase inhibitor ruxolitinib. Acta Derm Venereol. 2020;100(10):adv00144. https:\/\/doi.org\/10.2340\/00015555-3481.","journal-title":"Acta Derm Venereol."},{"key":"193_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab421","author":"M Shneyderman","year":"2021","unstructured":"Shneyderman M, Ahlawat S, Christopher-Stine L, Paik JJ. Calcinosis in refractory dermatomyositis improves with tofacitinib monotherapy: a case series. Rheumatology (Oxford). 2021. https:\/\/doi.org\/10.1093\/rheumatology\/keab421.","journal-title":"Rheumatology (Oxford)"},{"key":"193_CR36","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-kinase inhibitor tofacitinib - a report of two cases. J Autoimmun. 2019;100:131\u20136. https:\/\/doi.org\/10.1016\/j.jaut.2019.03.003.","journal-title":"J Autoimmun"},{"issue":"3","key":"193_CR37","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/dth.14939","volume":"34","author":"A Paudyal","year":"2021","unstructured":"Paudyal A, Zheng M, Lyu L, et al. JAK-inhibitors for dermatomyositis: a concise literature review. Dermatol Ther. 2021;34(3):e14939. https:\/\/doi.org\/10.1111\/dth.14939.","journal-title":"Dermatol Ther"},{"key":"193_CR38","doi-asserted-by":"publisher","first-page":"585761","DOI":"10.3389\/fphar.2020.585761","volume":"11","author":"W Conca","year":"2020","unstructured":"Conca W, Weheba I, Abouzied ME, et al. The inexorable advance of tofacitinib in the treatment of dermatomyositis-associated rapidly progressive interstitial lung disease. A case report. Front Pharmacol. 2020;11:585761. https:\/\/doi.org\/10.3389\/fphar.2020.585761.","journal-title":"Front Pharmacol"},{"key":"193_CR39","doi-asserted-by":"publisher","first-page":"108451","DOI":"10.1016\/j.clim.2020.108451","volume":"215","author":"A Takatani","year":"2020","unstructured":"Takatani A, Koga T, Fujita Y, et al. Efficacy of tofacitinib for slowly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis. Clin Immunol. 2020;215:108451. https:\/\/doi.org\/10.1016\/j.clim.2020.108451.","journal-title":"Clin Immunol"},{"issue":"1","key":"193_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/24725625.2020.1816674","volume":"5","author":"SI Ohmura","year":"2021","unstructured":"Ohmura SI, Yamabe T, Naniwa T. Successful dose escalation of tofacitinib for refractory dermatomyositis and interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibodies. Mod Rheumatol Case Rep. 2021;5(1):76\u201381. https:\/\/doi.org\/10.1080\/24725625.2020.1816674.","journal-title":"Mod Rheumatol Case Rep"},{"issue":"12","key":"193_CR41","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018;57(12):2114\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/key188.","journal-title":"Rheumatology (Oxford)"},{"key":"193_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/art.41944","author":"JJ Paik","year":"2021","unstructured":"\u2022\u2022 Paik JJ, Shneyderman M, Gutierrez-Alamillo L, et al. Long term extension study of tofacitinib in refractory dermatomyositis. Arthritis Rheumatol. 2021. https:\/\/doi.org\/10.1002\/art.41944. This letter summarizes long-term extension data of tofacitinib in refractory dermatomyositis from the study above and shows sustained clinical efficacy of the drug.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"193_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381(3):291\u20133. https:\/\/doi.org\/10.1056\/NEJMc1900045.","journal-title":"N Engl J Med"},{"key":"193_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2021.1906505","volume":"2021","author":"S Takanashi","year":"2021","unstructured":"Takanashi S, Kaneko Y, Takeuchi T. Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: a literature review. Mod Rheumatol. 2021;2021:1\u20137. https:\/\/doi.org\/10.1080\/14397595.2021.1906505.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"193_CR45","doi-asserted-by":"publisher","first-page":"R176","DOI":"10.1186\/ar2865","volume":"11","author":"M Cutolo","year":"2009","unstructured":"Cutolo M, Soldano S, Montagna P, et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res Ther. 2009;11(6):R176. https:\/\/doi.org\/10.1186\/ar2865.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"193_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","volume":"160","author":"B Arabshahi","year":"2012","unstructured":"Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160(3):520\u20132. https:\/\/doi.org\/10.1016\/j.jpeds.2011.11.057.","journal-title":"J Pediatr"},{"key":"193_CR47","doi-asserted-by":"publisher","first-page":"4073879","DOI":"10.1155\/2020\/4073879","volume":"2020","author":"S Sukumaran","year":"2020","unstructured":"Sukumaran S, Vijayan V. Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol. 2020;2020:4073879. https:\/\/doi.org\/10.1155\/2020\/4073879.","journal-title":"Case Rep Rheumatol."},{"issue":"10","key":"193_CR48","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1093\/rheumatology\/key146","volume":"57","author":"M Rodziewicz","year":"2018","unstructured":"Rodziewicz M, Kiely P. The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease. Rheumatology (Oxford). 2018;57(10):1866\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/key146.","journal-title":"Rheumatology (Oxford)"},{"issue":"Pt 7","key":"193_CR49","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/brain\/aww122","volume":"139","author":"R Lahoria","year":"2016","unstructured":"Lahoria R, Selcen D, Engel AG. Microvascular alterations and the role of complement in dermatomyositis. Brain. 2016;139(Pt 7):1891\u2013903. https:\/\/doi.org\/10.1093\/brain\/aww122.","journal-title":"Brain"},{"issue":"6","key":"193_CR50","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314(6):329\u201334. https:\/\/doi.org\/10.1056\/NEJM198602063140601.","journal-title":"N Engl J Med"},{"issue":"12","key":"193_CR51","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1001\/archderm.1995.01690240040007","volume":"131","author":"JM Mascar\u00f3","year":"1995","unstructured":"Mascar\u00f3 JM, Hausmann G, Herrero C, Grau JM, Cid MC, Palou J. Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch Dermatol. 1995;131(12):1386\u201392. https:\/\/doi.org\/10.1001\/archderm.1995.01690240040007.","journal-title":"Arch Dermatol"},{"issue":"12","key":"193_CR52","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3899\/jrheum.180060","volume":"45","author":"S Faguer","year":"2018","unstructured":"Faguer S, Belliere J, Ribes D. Complement C5-blocking agent in refractory dermatomyositis. J Rheumatol. 2018;45(12):1710\u20131. https:\/\/doi.org\/10.3899\/jrheum.180060.","journal-title":"J Rheumatol"},{"issue":"1","key":"193_CR53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/1546-0096-12-S1-P275","volume":"12","author":"F Vanoni","year":"2014","unstructured":"Vanoni F, Jorgensen C, Parvex P, Chizzolini C, Hofer M. A difficult case of juvenile dermatomyositis complicated by thrombotic microangiopathy and Purtscher-like retinopathy. Pediatr Rheumatol Online J. 2014;12(1):275.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"193_CR54","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jdcr.2018.11.019","volume":"5","author":"C Bitar","year":"2019","unstructured":"Bitar C, Maghfour J, Ho-Pham H, Stumpf B, Boh E. Apremilast as a potential treatment for moderate to severe dermatomyositis: a retrospective study of 3 patients. JAAD Case Rep. 2019;5(2):191\u20134. https:\/\/doi.org\/10.1016\/j.jdcr.2018.11.019.","journal-title":"JAAD Case Rep"},{"issue":"4","key":"193_CR55","doi-asserted-by":"publisher","first-page":"657","DOI":"10.21873\/invivo.11108","volume":"31","author":"M Giri\u015f","year":"2017","unstructured":"Giri\u015f M, Durmu\u015f H, Yetimler B, Ta\u015fli H, Parman Y, T\u00fcz\u00fcn E. Elevated IL-4 and IFN-\u03b3 levels in muscle tissue of patients with dermatomyositis. In Vivo. 2017;31(4):657\u201360. https:\/\/doi.org\/10.21873\/invivo.11108.","journal-title":"In Vivo"},{"issue":"16","key":"193_CR56","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Beh\u00e7et\u2019s syndrome\u2013a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138. https:\/\/doi.org\/10.1056\/NEJMoa1408684.","journal-title":"N Engl J Med"},{"issue":"6","key":"193_CR57","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2016-210189","volume":"76","author":"C Maier","year":"2017","unstructured":"Maier C, Ramming A, Bergmann C, et al. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages. Ann Rheum Dis. 2017;76(6):1133\u201341. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210189.","journal-title":"Ann Rheum Dis"},{"key":"193_CR58","unstructured":"Del Rio Oliva M, Basler M, Bomba D, Lam D, Brandl J, Kirk C, Groettrup M. KZR-616, a first-in-class selective inhibitor of the immunoproteasome, ameliorates polymyositis in a murine model [abstract]. Arthritis Rheumatol. 2020; 72(suppl 10). https:\/\/acrabstracts.org\/abstract\/kzr-616-a-first-in-class-selective-inhibitor-of-the-immunoproteasome-ameliorates-polymyositis-in-a-murine-model\/. Accessed 27 Jan 2022."},{"issue":"6","key":"193_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/ar3531","volume":"13","author":"EC Baechler","year":"2011","unstructured":"Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther. 2011;13(6):249. https:\/\/doi.org\/10.1186\/ar3531.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"193_CR60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256\u201362. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202794.","journal-title":"Ann Rheum Dis"}],"container-title":["Current Treatment Options in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-022-00193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40674-022-00193-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-022-00193-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T13:33:23Z","timestamp":1668432803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40674-022-00193-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1007\/s40674-022-00193-6","relation":{},"ISSN":["2198-6002"],"issn-type":[{"value":"2198-6002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"assertion":[{"value":"18 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. J. P. is supported in part by K23AR073927. J. J. P. has received clinical trial support from Pfizer and Kezar Inc., Advisory board and consulting fees from Pfizer, Kezar, EMD Serono, Roivant, Guidepoint Consulting.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}